HealthQuill Respiratory diseases
AstraZeneca’s lung cancer drug, Tagrisso, reduced the risk of death by 51% in the early stages of the disease, according to a company statement.
Drugs Health

AstraZeneca’s asthma drug fails end-stage trial in COPD

HQ Team September 17, 2025: AstraZeneca’s asthma drug Fasenra (benralizumab) has  failed to meet its primary goal in a Phase III trial for.

Read More
Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate of worsening episodes in adults with moderate-to-severe asthma, according to a statement.
Drugs Health Pharma

Sanofi’s test drug to treat moderate-to-severe asthma fails to meet goals 

HQ Team April 17, 2025: Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate.

Read More
Pneumonia is a form of acute respiratory infection that affects the lungs and kills more children than any other infectious disease. Every day at least one child dies from pneumonia every 43 seconds, according to UNICEF.
Drugs Health Pharma

Opinion: Steps for prevention, spread, and monitoring pneumonia

By K. Leelamoni November 5, 2023: Outbreaks of pneumonia affecting children in parts of northern China, the US,  the Netherlands, and Denmark are higher than.

Read More
The World Health Organisation is monitoring an increase in children’s illness caused by pathogens, including acute respiratory syndrome coronavirus 2, in northern China.
Climate Health Pharma

WHO keeping an eye on a surge of respiratory illness in northern China

The World Health Organization is monitoring an increase in children’s illness caused by pathogens, including acute respiratory syndrome coronavirus 2, in northern China.

Read More
An advisory panel of the national public agency of the US, Centers for Disease Control and Prevention, has provisionally recommended Pfizer’s vaccine for respiratory syncytial virus in pregnant women to protect infants during the infection season.
Drugs Health Pharma

CDC panel backs Pfizer’s respiratory virus vaccine to protect infants 

HQ Team September 23, 2023: An advisory panel of the national public agency of the US, Centers for Disease Control and Prevention, has.

Read More
An advisory committee of the USFDA has given a “favourable benefit-risk profile” for Sanofi and AstraZeneca’s experimental drug nirsevimab, meant to treat lower respiratory tract disease in newborns, according to a statement from the Paris-based firm.
Drugs Health Pharma

FDA’s advisory panel backs Sanofi, AstraZeneca’s investigational drug for newborns

HQ Team June 9, 2023: An advisory committee of the USFDA has given a “favourable benefit-risk profile” for Sanofi and AstraZeneca’s experimental drug.

Read More